Drugs / CX1106
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04093115 | Dec 2019 → Mar 2020 | head and neck squamous cell carcinoma | Beijing Konruns Pharmaceutical Co., Ltd. | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CX1106 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04093115 ↗ |
| Action | Inhibit | “CX1106 is a novel inhibitor of thymidylate synthase (TS)” NCT04093115 ↗ |
| Route | Other | “as a 24-hour continuous infusion” NCT04093115 ↗ |